The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.
There is no information on the effect of food or concurrent drug administration on the bioavailability of oral etoposide, despite the fact that treatment is frequently administered over several days and most often in combination with other cytotoxic agents. The influence of these factors has been studied in 11 patients, receiving combination cytotoxic therapy for extensive small cell lung carcinoma. Neither food nor concurrent oral or intravenous chemotherapy had a significant effect on the mean plasma concentrations of etoposide, achieved following oral administration. Wide variation in peak plasma concentrations and in area under the concentration time curve (AUC) occurred both between and within patients. It appears unnecessary for patients receiving etoposide (at 100 mg) to fast prior to drug administration. Furthermore, oral etoposide (at 100 mg and at 400 mg) may be given in combination with other cytotoxic agents without compromising its bioavailability.
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001682:Biological Availability; D018288:Carcinoma, Small Cell / Q000378:metabolism*; D004347:Drug Interactions; D005047:Etoposide / Q000008:administration & dosage / Q000378:metabolism*; D005502:Food; D006801:Humans; D007700:Kinetics; D008175:Lung Neoplasms / Q000378:metabolism*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D005047:Etoposide; D011034:Podophyllotoxin